Retrophin Inc (NASDAQ:RTRX) – Investment analysts at Leerink Swann issued their FY2019 EPS estimates for shares of Retrophin in a report released on Tuesday. Leerink Swann analyst J. Schwartz forecasts that the biopharmaceutical company will post earnings of ($0.11) per share for the year.
A number of other brokerages also recently weighed in on RTRX. BMO Capital Markets lowered their target price on shares of Retrophin from $46.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, March 2nd. Zacks Investment Research raised shares of Retrophin from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, March 7th. Finally, William Blair reaffirmed an “outperform” rating on shares of Retrophin in a research note on Thursday, April 6th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $32.25.
Retrophin (NASDAQ:RTRX) traded down 1.38% during mid-day trading on Friday, hitting $18.58. 186,140 shares of the stock were exchanged. Retrophin has a 52 week low of $13.31 and a 52 week high of $24.57. The stock’s 50-day moving average is $18.63 and its 200 day moving average is $19.84. The company’s market capitalization is $707.77 million.
Large investors have recently made changes to their positions in the stock. HBK Investments L P bought a new stake in shares of Retrophin during the third quarter worth $291,000. Consonance Capital Management LP increased its stake in shares of Retrophin by 14.3% in the third quarter. Consonance Capital Management LP now owns 3,084,947 shares of the biopharmaceutical company’s stock worth $69,041,000 after buying an additional 385,000 shares in the last quarter. Sphera Funds Management LTD. increased its stake in shares of Retrophin by 26.7% in the third quarter. Sphera Funds Management LTD. now owns 190,000 shares of the biopharmaceutical company’s stock worth $4,252,000 after buying an additional 40,000 shares in the last quarter. Gargoyle Investment Advisor L.L.C. bought a new stake in shares of Retrophin during the third quarter worth $206,000. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Retrophin during the third quarter worth $1,676,000.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc and related companies with MarketBeat.com's FREE daily email newsletter.